Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ORKA |
---|---|---|
09:32 ET | 894 | 26.13 |
09:50 ET | 277 | 27.162 |
10:03 ET | 1900 | 27.15 |
10:08 ET | 400 | 26.07 |
10:10 ET | 100 | 26.54 |
10:24 ET | 600 | 26.105 |
10:28 ET | 200 | 26.03 |
10:30 ET | 200 | 25.98 |
10:37 ET | 1500 | 26.02 |
10:39 ET | 400 | 25.97 |
10:42 ET | 700 | 26.05 |
10:44 ET | 376 | 25.98 |
10:46 ET | 300 | 26.195 |
10:48 ET | 5500 | 26.195 |
10:50 ET | 300 | 26.23 |
10:51 ET | 3269 | 26.055 |
10:53 ET | 200 | 25.63 |
10:55 ET | 200 | 26 |
10:57 ET | 1940 | 26 |
11:02 ET | 500 | 25.8 |
11:22 ET | 933 | 25.7311 |
11:29 ET | 100 | 25.71 |
11:33 ET | 182 | 25.9013 |
11:36 ET | 1000 | 25.0101 |
12:03 ET | 100 | 25.3 |
12:32 ET | 100 | 25.55 |
01:03 ET | 250 | 25.1742 |
01:08 ET | 1308 | 25.5 |
01:14 ET | 100 | 25.94 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Oruka Therapeutics Inc | 906.5M | -4.3x | --- |
Perspective Therapeutics Inc | 884.7M | -9.4x | --- |
89Bio Inc | 869.5M | -4.2x | --- |
IGM Biosciences Inc | 939.6M | -5.3x | --- |
Sana Biotechnology Inc | 970.0M | -3.8x | --- |
Cullinan Therapeutics Inc | 981.5M | -5.7x | --- |
Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $906.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.91 |
EPS | $-5.97 |
Book Value | $30.64 |
P/E Ratio | -4.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.